ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report.

ICER said that the incremental cost effectiveness ratios of the biologics as add-on maintenance therapies ranged from $325,000 to $391,000 per quality-adjusted life years (QALY). Commonly cited thresholds for cost-effectiveness are $50,000-$150,000 per QALY. In probabilistic sensitivity analyses, including a modified societal perspective, no biologic achieved a greater than zero likelihood of meeting the $150,000/QALY or lower threshold...